Literature DB >> 21547130

Levels of matrix metalloproteinase-1 and tissue inhibitors of metalloproteinase-1 in gastric cancer.

Ozgur Kemik1, Ahu Sarbay Kemik, Aziz Sümer, Ahmet Cumhur Dulger, Mine Adas, Huseyin Begenik, Ismail Hasirci, Ozkan Yilmaz, Sevim Purisa, Erol Kisli, Sefa Tuzun, Cetin Kotan.   

Abstract

AIM: To evaluate the levels of preoperative serum matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in gastric cancer.
METHODS: One hundred gastric cancer patients who underwent gastrectomy were enrolled in this study. The serum concentrations of MMP-1 and TIMP-1 in these patients and in fifty healthy controls were determined using an enzyme-linked immunosorbent assay.
RESULTS: Higher serum MMP-1 and TIMP-1 levels were observed in patients than in controls (P < 0.001). Serum MMP-1 and TIMP-1 levels were positively associated with morphological appearance, tumor size, depth of wall invasion, lymph node metastasis, liver metastasis, perineural invasion, and pathological stage. They were not significantly associated with age, gender, tumor location, or histological type.
CONCLUSION: Increased MMP-1 and TIMP-1 were associated with gastric cancer. Although these markers are not good markers for diagnosis, these markers show in advanced gastric cancer.

Entities:  

Keywords:  Gastric cancer; Matrix metalloproteinase-1; Tissue matrix metalloproteinase-1

Mesh:

Substances:

Year:  2011        PMID: 21547130      PMCID: PMC3084396          DOI: 10.3748/wjg.v17.i16.2109

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  27 in total

Review 1.  Matrix metalloproteinases.

Authors:  H Nagase; J F Woessner
Journal:  J Biol Chem       Date:  1999-07-30       Impact factor: 5.157

Review 2.  Tissue inhibitors of metalloproteinases: evolution, structure and function.

Authors:  K Brew; D Dinakarpandian; H Nagase
Journal:  Biochim Biophys Acta       Date:  2000-03-07

3.  Matrix metalloproteinase-1 and tissue inhibitor of metalloproteinases-1 levels in severely obese patients: what is the effect of weight loss?

Authors:  D Papazoglou; K Papatheodorou; N Papanas; T Papadopoulos; T Gioka; G Kabouromiti; S Kotsiou; E Maltezos
Journal:  Exp Clin Endocrinol Diabetes       Date:  2010-04-01       Impact factor: 2.949

4.  Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker.

Authors:  Chia-Siu Wang; Tsu-Lan Wu; Kuo-Chien Tsao; Chien-Feng Sun
Journal:  Ann Clin Lab Sci       Date:  2006       Impact factor: 1.256

5.  Crevicular fluid matrix metalloproteinase-8, -13, and TIMP-1 levels in type 2 diabetics.

Authors:  L Kardeşler; B Biyikoğlu; S Cetinkalp; M Pitkala; T Sorsa; N Buduneli
Journal:  Oral Dis       Date:  2010-03-09       Impact factor: 3.511

6.  MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer.

Authors:  E Sunami; N Tsuno; T Osada; S Saito; J Kitayama; S Tomozawa; T Tsuruo; Y Shibata; T Muto; H Nagawa
Journal:  Oncologist       Date:  2000

7.  PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells.

Authors:  Adrienne Boire; Lidija Covic; Anika Agarwal; Suzanne Jacques; Sheida Sherifi; Athan Kuliopulos
Journal:  Cell       Date:  2005-02-11       Impact factor: 41.582

8.  Clinical relevance of the expression of mRNA of MMP-7, MMP-9, TIMP-1, TIMP-2 and CEA tissue samples from colorectal liver metastases.

Authors:  A Sutnar; M Pesta; V Liska; V Treska; T Skalicky; S Kormunda; O Topolcan; R Cerny; L Holubec
Journal:  Tumour Biol       Date:  2007-11-09

9.  Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer.

Authors:  Marja Hilska; Peter J Roberts; Yrjö U Collan; Veli Jukka O Laine; Jyrki Kössi; Pirkko Hirsimäki; Otto Rahkonen; Matti Laato
Journal:  Int J Cancer       Date:  2007-08-15       Impact factor: 7.396

10.  Serum levels of matrix metalloproteinases -1,-2,-3 and -9 in thoracic aortic diseases and acute myocardial ischemia.

Authors:  Georgios T Karapanagiotidis; Polychronis Antonitsis; Nicholas Charokopos; Christophoros N Foroulis; Kyriakos Anastasiadis; Efthymia Rouska; Helena Argiriadou; Kyriakos Rammos; Christos Papakonstantinou
Journal:  J Cardiothorac Surg       Date:  2009-11-03       Impact factor: 1.637

View more
  9 in total

1.  PDGF-D promotes dermal fibroblast invasion in 3-dimensional extracellular matrix via Snail-mediated MT1-MMP upregulation.

Authors:  Zhuo Qin; Jinfa Feng; Yusi Liu; Li-Li Deng; Changlian Lu
Journal:  Tumour Biol       Date:  2015-08-04

2.  Molecular targeted therapies in advanced gastric cancer: does tumor histology matter?

Authors:  Hilda Wong; Thomas Yau
Journal:  Therap Adv Gastroenterol       Date:  2013-01       Impact factor: 4.409

3.  Fisetin suppresses ADAM9 expression and inhibits invasion of glioma cancer cells through increased phosphorylation of ERK1/2.

Authors:  Chien-Min Chen; Yi-Hsien Hsieh; Jin-Ming Hwang; Hsun-Jin Jan; Shu-Ching Hsieh; Shin-Huey Lin; Chung-Yu Lai
Journal:  Tumour Biol       Date:  2014-12-20

Review 4.  Molecular background of the regional lymph node metastasis of gastric cancer.

Authors:  Tong Zhu; Xueqian Hu; Pinkang Wei; Guangzhi Shan
Journal:  Oncol Lett       Date:  2018-01-16       Impact factor: 2.967

5.  Tissue Inhibitor of Metalloproteinase-1 Is Confined to Tumor-Associated Myofibroblasts and Is Increased With Progression in Gastric Adenocarcinoma.

Authors:  Warner Alpízar-Alpízar; Ole Didrik Laerum; Ib J Christensen; Kjell Ovrebo; Arne Skarstein; Gunilla Høyer-Hansen; Michael Ploug; Martin Illemann
Journal:  J Histochem Cytochem       Date:  2016-07-01       Impact factor: 2.479

Review 6.  Association between promoters polymorphisms of matrix metalloproteinases and risk of digestive cancers: a meta-analysis.

Authors:  Xiaoying Li; Lianxi Qu; Yu Zhong; Yingjie Zhao; Hongyan Chen; Lu Daru
Journal:  J Cancer Res Clin Oncol       Date:  2013-05-05       Impact factor: 4.553

7.  Licochalcone A inhibits the migration and invasion of human lung cancer cells via inactivation of the Akt signaling pathway with downregulation of MMP-1/-3 expression.

Authors:  Hung-Che Huang; Lo-Lin Tsai; Jen-Pi Tsai; Shu-Ching Hsieh; Shun-Fa Yang; Jung-Tsung Hsueh; Yi-Hsien Hsieh
Journal:  Tumour Biol       Date:  2014-08-23

8.  Serum Levels of Matrix Metalloproteinase-1 in Brazilian Patients with Benign Prostatic Hyperplasia or Prostate Cancer.

Authors:  William Khalil El-Chaer; Audrey Cecília Tonet-Furioso; Gilberto Santos Morais Junior; Vinícius Carolino Souza; Gleiciane Gontijo Avelar; Adriane Dallanora Henriques; Clayton Franco Moraes; Otávio Toledo Nóbrega
Journal:  Curr Gerontol Geriatr Res       Date:  2020-05-05

9.  Coexpression of Matrix Metalloproteinase-7 and Tissue Inhibitor of Metalloproteinase-1 as a Prognostic Biomarker in Gastric Cancer.

Authors:  Yangyu Zhang; Lili Qin; Xiaobo Ma; Yueqi Wang; Yanhua Wu; Jing Jiang
Journal:  Dis Markers       Date:  2020-09-14       Impact factor: 3.434

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.